Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Robert A. Dillman"'
Autor:
Candace Hsieh, Robert O. Dillman, Frank P.K. Hsu, Gabriel Nistor, David Piccioni, Christopher Duma, Santosh Kesari, Jose Carrillo, Robert Aiken, Thomas H. Taylor, Daniela A. Bota, Xiao-Tang Kong, Renato V. LaRocca, Mehrdad Abedi
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A358-A358
BackgroundDespite standard aggressive therapy (maximum safe surgical resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ), then maintenance TMZ), 2-year survival is only about 25% for patients with newly diagnosed primary gl
Autor:
Gabriel Nistor, Xiang-Tang Kong, Thomas H. Taylor, David Piccione, Robert O. Dillman, Jose Carrillo, Candace Hsieh, Christopher Duma, Daniela A. Bota, Santosh Kesari, Robert Aiken, Renato V. LaRocca, Mehrdad Abedi, Frank P.K. Hsu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundFor patients with newly diagnosed primary glioblastoma (GBM), maximum safe surgical resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ) followed by maintenance TMZ results in a 2-year survival of only 25%. Adding
Autor:
Thomas H. Taylor, Candace Hsieh, Xiao-Tang Kong, Frank P.K. Hsu, Gabriel Nistor, Christopher Duma, Santosh Kesari, Jose Carrillo, Aleksandra J. Poole, David Piccioni, Daniela A. Bota, Renato V. LaRocca, Mehrdad Abedi, Robert Aiken, Robert O. Dillman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundDespite standard aggressive therapy, including maximum safe surgical resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ) followed by maintenance TMZ, survival is still extremely poor for patients with newly diagno
Autor:
Jessica Cannon, Robert O. Dillman, Jia He, Chengwei Chen, William Wei Cao, Michael Bayer, Xiaojin Wang, Craig Fredrickson, Gabriel Nistor, Qingchun Fu, Xiaosong Chen, Andrew N. Cornforth
Publikováno v:
Journal for Immunotherapy of Cancer
Background Active or chronic infections may be barriers to successful vaccines, and patients with hepatitis typically are excluded from clinical trials testing therapeutic anticancer vaccines. One concern is vaccines may exacerbate the underlying inf
Publikováno v:
Journal for Immunotherapy of Cancer
Meeting abstracts Treatment with high-dose Interleukin-2 (IL-2) has been associated with long-term survival in small proportion of metastatic melanoma patients. We recently reported a median survival of 15.6 months, and a 20% 5-year survival rate for